Attempts to monitor coronary sinus adenosine as a clinical marker of myocardial ischemia in humans have been disappointing. Accordingly, procedures have been developed for detecting adenosine in blood collected from the human coronary sinus. Collection involves using a double-lumen metabolic catheter, which allows blood to be mixed with a stop solution at the catheter tip, thereby minimizing adenosine formation and degradation. A fivecomponent stop solution almost completely arrests adenosine formation and degradation. Adenosine analysis is improved by using both boronate and C18 Sep-Pak columns to purify and concentrate adenosine in human plasma before HPLC. Plasma adenosine in the coronary sinus of patients with and without coronary artery disease, measured before and during peak atnal pacing, showed a twofold atrial pacing-induced increase in adenosine in the patients with coronary artery disease (n = 9, P <0.001) but no change in the patients with normal epicardial coronary arteries (n = 6). These preliminary results Indicate that coronary sinus adenosine may provide an Index of myocardial ischemia in patients with coronary artery disease. Adenosme has been proposed as a likely metabolic signal released by the hypoxic or ischemic myocardium to elicit an increase in coronary blood flow in responseto a decrease in the oxygen supply/demand ratio (1). However, attempts to monitor coronary sinus adenosine as a clinical marker of myocardial ischemia in humans have been disappointing. An early report that adenosine is increased in the coronary sinus of patients with ischemic heart disease during pacing (2) was not reproduced in several subsequent studies in which more sensitive assay techniques were used (3) (4) (5) (6) . This may be because the half4ife of adenosine in hnmsin blood is <1.5 s (7) and because a large fraction of adenosine is taken up by endothelial cells (8) and other cellular blood elements (9). Only when the adenosine transport inhibitor dipyridamole was systemically infused before pacing could crease in coronary sinus adenosine in patients with coronary artery disease. We hypothesized that the inability to use blood adenosine concentrations as a metabolic marker of myocardial ischemia in patients might be due in part to methodological limitations. In current sampling techniques, catheters >100-cm long are used to draw blood from the coronary sinus. No solution to stop adenosine metabolism is included and therefore both degradation and artifactual production of adenosine are likely to occur during transit in these long catheters. Our objective was to develop methodology capable of detecting ischemia-induced increases of coronary artery adenosine.
Attempts to monitor coronary sinus adenosine as a clinical marker of myocardial ischemia in humans have been disappointing. Accordingly, procedures have been developed for detecting adenosine in blood collected from the human coronary sinus. Collection involves using a double-lumen metabolic catheter, which allows blood to be mixed with a stop solution at the catheter tip, thereby minimizing adenosine formation and degradation. A fivecomponent stop solution almost completely arrests adenosine formation and degradation. Adenosine analysis is improved by using both boronate and C18 Sep-Pak columns to purify and concentrate adenosine in human plasma before HPLC. Plasma adenosine in the coronary sinus of patients with and without coronary artery disease, measured before and during peak atnal pacing, showed a twofold atrial pacing-induced increase in adenosine in the patients with coronary artery disease (n = 9, P <0.001) but no change in the patients with normal epicardial coronary arteries (n = 6). These preliminary results Indicate that coronary sinus adenosine may provide an Index of myocardial ischemia in patients with coronary artery disease.
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Adenosme has been proposed as a likely metabolic signal released by the hypoxic or ischemic myocardium to elicit an increase in coronary blood flow in responseto a decrease in the oxygen supply/demand ratio (1). However, attempts to monitor coronary sinus adenosine as a clinical marker of myocardial ischemia in humans have been disappointing. An early report that adenosine is increased in the coronary sinus of patients with ischemic heart disease during pacing (2) was not reproduced in several subsequent studies in which more sensitive assay techniques were used (3) (4) (5) (6) . This may be because the half4ife of adenosine in hnmsin blood is <1.5 s (7) and because a large fraction of adenosine is taken up by endothelial cells (8) and other cellular blood elements (9) . Only when the adenosine transport inhibitor dipyridamole was systemically infused before pacing could Sollevi et al. (4, 5) demonstrate a pacing-induced inDepartments of 1 Internal Medicine and' BiomedicalEngineering, University of Virginia Health SciencesCenter, Charlottesville, VA 22908. 2Addreeacorrespondence to this authorat Division of Cardiology, Box 158, University of Virginia Health SciencesCenter, Charlottesville, VA 22908.
ReceivedJune 4, 1991; acceptedDecember27, 1991. crease in coronary sinus adenosine in patients with coronary artery disease. We hypothesized that the inability to use blood adenosine concentrations as a metabolic marker of myocardial ischemia in patients might be due in part to methodological limitations. In current sampling techniques, catheters >100-cm long are used to draw blood from the coronary sinus. No solution to stop adenosine metabolism is included and therefore both degradation and artifactual production of adenosine are likely to occur during transit in these long catheters. Our objective was to develop methodology capable of detecting ischemia-induced increases of coronary artery adenosine.
MaterIals and Methods

Sample Collection
We developed a double-lumen metabolic catheter (U.S. patent 5,009,634), which allows addition and mixing of a stop solution to blood entering the tip of the catheter. Figure IA is a schematic diagram of the catheter, which has two lumens, consisting of an outer catheter (8F multipurpose) and an inner catheter (2.5F) ending 1 cm from the end of the outer catheter (Figure tB). A prototype of this catheter was described previously (10) . The outer and inner catheters are connected by a Y-adaptor.
Blood and stop solution movement through the outer and inner catheters are coupled by a double-syringe device. The larger collection syringe holds 6 mL, whereas the smaller infusion syringe holds 3 mL. The smaller syringe, being half the cross-sectional area of the larger syringe, ensures equivolume mining of blood with stop solution at the tip of the metabolic catheter. During patient studies, the plunger is pulled out of the collection syringe and blood flows into the outer catheter and the collection syringe. As the plunger on the collection syringe is being pulled out, the second plunger is pushed into the infusion syringe, infusing stop solution through the inner catheter so that mining between the stop solution and blood occurs at the distal end of the metabolic catheter. Both catheters are primed with stop solution before the blood is withdrawn. 4 Peripheral venous blood samples from volunteers were used to validate the assay with use of the above five-component stop solution. To eliminate the possibility of accidentally injecting AOPCPand EHNA into patients, we omitted these two components from the stop solution when we used the metabolic catheter to withdraw blood from the coronary sinus. However, supplemental stock solutions of AOPCP and EHNA were added to the collection syringe to mix with the blood as it was collected. The stop solution in the infusion syringe and the dead space in the metabolic catheter between the inner and outer catheters and within the inner catheter were primed with dipyridarnole, EDTA, and heparin at the concentrations listed above. We injected 0.2 mL of concentrated EHNA and AOPCP into the withdrawal syringe, giving final concentrations the same as above, once the blood, dipyridamole, EDTA, and heparin were mixed in the collection syringe. filtered through a 0.2-sm (pore size) filter (Acrodisc; Gelman Sciences, Ann Arbor, MI), and 106 pmol of The amount of adenosine in each sample was determined by comparing the observed peak area with a standard curve. The amount of plasma assayed was calculated as follows:5
Because half of the sample was injected onto the HPLC column, this result was divided by 2. For a normal Hct of 0.40, the assayed plasma volume is 74 ,uL of plasma. The concentration of adenosine in plasma was then calculated by dividing the amount of adenosine measured by the volume of plasma assayed, with correction for recovery of the internal standard, which ranged from 50% to 65%.
Assay Verification
Coefficient of variation.
A 4-mL peripheral venous blood sample was collected from a volunteer into 12 mL of stop solution through a 2.5-cm, 19-gauge needle. The supernate was divided into seven 1-mL portions and processed as above. The mean, SD, and CV determined from these seven samples were 0.186 and 0.034 moIfL and 18.3%, respectively. Because the CV was >10%, all results presented are the means of duplicate determinations.
Recovery of aclenosine and internal standard during sample preparation.
To verify that the recoveries of both adenosine and N6-methyladenosine were the same, we added 18.7 pmol of adenosine and 106 pmol of internal
Sample Preparationand Analysis
Immediately after collection, the blood sample was centrifuged at 4800 x g for 2 mm. Each supernate was 4Nonatandard abbreviations: ERNA, e,'ythro-9(2-hydroxy-3-nonyl)-adenine; AOPCP, a,-methylene-adenosine diphosphate; Re, Reynolds numbers; and Hct, hematocrit. 5Th1s equation was derived as follows: The total volumeof blood/stop solution in the collectionsyringe is 4 mL, of which 0.2 mL is AOPCP/EHNA, 2.9 mL is stop solution,,and 0.9 rnL is blood. The plasma volume collected = 0.9mL (1-Hct). Thetotalvolume collected minus erythrocytes =4 mL -(0.9 mLXHct). Therefore, each 1 mL of collected sample contains a volumeof plasma given by 1 mL{0.9mL standard to 1 mL of stop solution and processed and analyzed this sample as above. The chromatographic peak areas were compared with those for identical amounts of adenosine and internal standard injected directly onto the HPLC column. Duplicate samples were analyzed on three separate occasions (n = 6).
Linear recovery of adenosine added to plasma.
We collected 4 mL of blood in 12 mL of stop solution as described above. The supernatant fluid from this sample was divided into six 1-mL portions, to which we added adenosine (0, 4.7, 9.4, 18.7, 28.1, and 37.4 pmol) and processed the samples as above. The amount of adenosine detected was plotted as a function of adenosine added.
Effect of adenosine deaminase on HPLC profiles. We collected blood as in the preceding section but divided the supernate into two portions. One portion was processed as described above. The second portion was processed similarly except that the dried samples were reconstituted with 200 iL of adenosine deaminase (2 kU/L added to HPLC-grade H20; Sigma Chemical Co.). After letting the samples sit at room temperature for 20 mm, we added 200 p.L of KH2PO4 (10 mmol/L, pH 3.6) to each sample. The deaminase was inactivated by boiling for 3 mm, and the sample was filtered as before and injected onto the HPLC column. We did not add internal standard to the sample to be deaminated because it was a substrate for the enzyme.
Stop-Solution Verification
To determine the extent to which adenosine breakdown is arrested by the metabolic catheter when dipyridamole, EDTA, and heparin are added at its tip and EENA and AOPCPare added in the collection syringe, we performed the following experiment. Peripheral venous blood (3.6 mL) was drawn from a volunteer into heparin (25 kilo-int. unita/L). The blood was immediately dispensed into 11.6 mL of dipyridamole and EDTA solution (at concentrations given in Sample Collection) containing 16 L of [14C]adenosine (New England Nuclear, Boston, MA; specific activity 57.2 Ci/mol; 58 159 dpm/mL in blood plus stop solution). At 9 and 60s after withdrawal of blood from the volunteer, 0.8 mL of EHNA and AOPCP were added (9 s is the average transit time for blood in the metabolic catheter). Blood, five-component stop solution, and PC]adenosine were centrifuged at 2500 x g for 1.5 ruin, and the supernate was removed. We added 50 L of trichloroacetic acid solution (final concentration in supernate, 50 g/L) to 950 pL of supernate and centrifuged at 2500 x g for 1 mm. We then mixed 0.5 mL of this supernate with 0.5 mL of ti-noctylamine (0.5 mmol/L) in Freon and centrifuged again at 2500 x g for 1 mm. We injected 50 1zL of the top (aqueous) layer into the HPLC column and continuously monitored the radioactivity with a Beckman 171 radioisotope detector. To determine the extent to which AMP is degraded, we substituted 483 pL of ["CUJ)]AMP (specific activity 590 Ciimol; 71713 dpni/mL in blood plus stop solution) for [ 
Metabolic Catheter Verification
A model of the metabolic catheter was built to verify that the stop solution and blood are mixed at its tip. We used a precision-bore glass tube to simulate the outer catheter, to allow a direct microscopic view of flow at the tip. An inner catheter was inserted into the glass tube, and the coupled syringe system was connected to an infusion-withdrawal pump to control the flow rate. The open end of the glass tube was located in a small reservoir with a pressure of 1-3 cm of H20 (-100-300 Pa), simulating the coronary sinus. 
Studies wfth Patients
Fifteen patients with a history of stable angina pectons or atypical chest pain were chosen from the elective cardiac catheterization schedule. Six of these patients were found to have normal epicardial coronary arteries and left ventriculography.
The other nine had two-or three-vessel coronary artery disease, with at least one stenosis >70%. Patients were identified 18 h before catheterization and were approached for consent. All medications were stopped at this time.
We waited 30 miii between the routine diagnostic catheterization and the research protocol. The atrial pacing stages were 100,120, and 140 beats/ruin, each for 2 miii, with a final stage of 160 beats/ruin for 5-7 mm. We measured baseline and peak pacing coronary sinus adenosine, simultaneous coronary sinus and aortic lactate and oxygen saturation, heart rate, and blood pressure, and obtained a 12-lead electrocardiogram.
Results
Assay Verification
Recovery of adenosine and internal standard during sample preparation. In three paired samples (ii =6) the percentage recoveries for adenosine and N6-methyladenosine through all steps of the assay, from preparation for boronate column application to reconstitution in phosphate buffer, were 61.9 (SD 7.0)% and 61.1 (SD 5.5)%, respectively (not significantly different).
Analytical recovery of adenosine added to plasma. The amount of adenosine detected by the assay was linearly related (r2 = 0.97) to the amount of exogenousadenosine added to plasma. In addition, the slope of the regression line was near unity (0.973), and the sum of endogenous and added adenosine was close to the predicted value (y = 17.61 + 0.973x). Effect of adenosine deaminase on HPLC profiles. Figure 3 depicts chromatograms for paired samples obtained from the same volunteer. One sample of each pair was incubated with adenosine deamunase; the other was not. Adenosine deaminase e1iminited the adenosine peak, indicating that this peak was indeed adenosine. (We did not add internal standard to the sample to be denminted because it was a substrate for the enzyme.)
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Studieswith Patients
Patients' results are displayed in Table 1 . There was no difference in baseline heart rates, but the normal group attained a higher peak heart rate during atrial pacing. There was no difference in the baseline or peak atrial pacing rate-pressure products between the normal and coronary artery disease groups. Seven of nine coronary artery disease patients had normal baseline electrocardiograms and developed >1.5 mm ST-segment depression. The other two patients also developed >1.5 mm ST-segment depression, but the electrocardiogram changes with atnial pacing were nondiagnostic because their baseline electrocardiograms were abnormal, with ST-segment depression. One of six normal patients with ST-segment depression at baseline developed >1.5 mm ST depression with atnial pacing. Eight of nine coronary artery disease patients developed reproduction of their typical angina with atnial pacing, whereas only one of six normal patients developed reproduction of their typical chest pain symptoms with pacing.
There was no difference at baseline or change with pacing in the aortocoronary sinus oxygen content difference between the coronary artery disease and normal groups. Only three of the nine patients with coronary artery disease had lactate production, defined as the myocardial lactate extraction fraction becoming negative,although the coronary artery disease group as a whole had a decrease in the extraction fraction. There was no change in the myocardial lactate extraction fraction forthe normal group. There was no difference in the baseline coronary sinus adenosine concentration between the two groups; every patient in the coronary artery diseasegroup had an increase in coronary sinus adenosine of 1.5-fold (Figure 4) .There was no change in coronary sinus adenosine with atrial pacing in the normal group.
Discussion
These results suggest that adenosine in coronary sinus blood is consistently increased during myocardial ischemia. The equivocal results of previous studies in which attempts were made to correlate blood adenosine with myocardial ischemia in patients may have been due to methodological limitations. We used a doublelumen metabolic catheter and a modified stop solution to prevent artifactual production of adenosine by the use of inhibitors of 5'-nucleotidase. Using these techniques, we obtained plasma samples that showed that nine of nine patients with coronary artery disease responded to pacing-induced ischemia with a 1.5-fold increase in coronary sinus adenosine, whereas only three of the nine had lactate production. Adenosine has a half-life of <1.5 a in human blood (7) . To detect increases in coronary sinus adenosine resulting from myocardial ischemia, one must quickly arrest A double-syringe device was introduced by Ontyd and Schrader (12) to address this need. This device allowed stop solution to be added at the entrance of the syringe collecting blood. However, such a device will not arrest the adenosine metabolism that occurs as the blood travels through a catheter. Because long catheters must be used to sample blood from the human coronary sinus, the only practical way to arrest the metabolism of adenosine is by injecting metabolicinhibitors at the tip of the sampling catheter. The utility of such a metabolic catheter has been validated in vitro by Shryock et al. (10) and applied clinically in the present study. We built a model of the metaboliccatheterto ensure that miring of blood and stop solution occurs at its tip. Moreover, in all patients' studies, we used a flow rate at which adequate miTing occurred (0.33 mLds). The use of this catheter may explain why this study demonstrates ischemia-induced increases in coronary sinus adenosine in the absence of systemicdipyridamole, even though no such changes could be detected in earlier studies (3) (4) (5) (6) .
The coronary sinus adenosine concentrations reported here are lower than in studieswhere inhibitors of
5'-nucleotidaae
were not incorporated into the stop solution ( Table 2) . Hamm et al. (6) did not use an adenosine deaininase inhibitor, which may have contributed to the low concentrations of adenosine they detected. The low concentrations of coronary sinus adenosine we detected here suggest that artifactual production of adenosine is an important source of error in studies dealing with whole human blood. Studies in which the highest concentrations of coronary sinus adenosine were reported used stop solutions designed to prevent loss but not production of adenosine. The stop solutions in these studies included dipyridamole (3,4, 13), EHNA (3,4) , or MnC12 (13) to prevent cellular uptake of adenosineor to inhibitadenosine deaminase. However, for accurate assessment of adenosine concentrations in blood, one must prevent adenosine formation. Because adenosine might be formed from adeninenucleotides released as a resultof platelet aggregation(14), Sollevi et al. (4, 5) added indomethacin to prevent platelet aggregates. However, adenine nucleotides may also be derived from even slight lysis of erythrocytes, which may occur during collection of coronary sinus blood samples. The #{176} Inhibitors of artifactual adenosine production were in thestopsolution.
enzymes necessary to degrade adenine nucleotides to adenosine also are present in human blood (15) . In the present study, we incorporated inhibitors of 5'-nucleotidease (AOPCP and EDTA) into the stop solution. Although, to ensure patient safety, we could place AOPCP only in the collection syringe, EDTA could be infused at the tip of the metabolic catheter.
Previous studies with HPLC were hampered by the presence in human plasma of several substances that are eluted near adenosine. Although some early reports quantified adenosine directly (16, 17) , more recent investigators have used peak-shift methodology (10, 12) . In the latter technique, an HPLC fraction containing adenosine is collected, deaminated, and injected for a second HPLC run; the amount of inosine is then quantified. McCann and Katholi (18) recently described preparing fluorescent etheno-derivatives of adenosine but still rechromatographed the human blood samples to remove interfering substances. If adenosine is to be used in patient care, simplification of methods for quantifying adenosine in human blood would be advantageous. We combined the use of boronate and C18 Sep-Pak precolunms to partially purify and concentrate the adenosine in plasma before HPLC; thus, we could quantify the adenosine accurately as an overnight procedure with a single isocratic HPLC step. Although boronate (4,17) and C18 Sep-Pak columns (7,19) have been used individually in assays of adenosine, their combined use was not previously reported.
An outgrowth of this study may be the physiological assessment of coronary artery disease at the time of cardiac catheterization. Clinical decisions regarding revascularization vs drug therapyare largelyaffected by the percentage of stenosis revealed by coronary angiography, currently the "gold standard"
by which the functional severity of coronary disease is evaluated. Many studies, however, document marked variability in interpretations of the severity of a stenosis (20, 21) , and autopsy studies have demonstrated a lack of correlation with arteriography (22) . Thus new methods are needed for better physiological assessment of coronary artery stenoses.
There are several limitations to the methodology we have presented. First, we have not accounted for the effect of pacing-induced changes in arterial adenosine concentration or coronary sinus blood flow on the concentration of coronary sinus adenosine. Because pacing is associated with increased coronary sinus blood flow (23) , the increase in adenosine plasma concentration in the coronary artery disease patients probably underestimates the true change in the magnitude of adenosine production. A second limitation is that we cannot distinguish between adenosine derived from ischemic myocardium and that from other sources such as the vascular endotheliuni (24, 25) , blood cells (15), and nerves (26). Nonetheless, this study establishes adenosine as a marker of myocardial ischemia, regardless of the precise mechaniam by which it is released. A third limitation is the inability of the metabolic catheter to 262 CLINICAL CHEMISTRY, Vol. 38, No. 2, 1992 sample regional myocardial adenosine production, especially from the right coronary artery. This catheter samples coronary sinus blood, a reflection of global myocardial adenosine release, whereas coronary artery disease and ischemia affect the myocardium in a focal manner. Adenosine released from nonischemic myocardium will, to a certain extent, be mixed with adenosine from ischemic myocardium and sampled together when blood is drawn from the coronary sinus. Another limitation is a time delay for blood transit from the myocardial capillaries to the metabolic catheter in the coronary sinus, during which time metabolism of adenosine can occur. This may explain why we cannot detect pacinginduced increases in coronary sinus adenosine in patients with normal epicardial coronary arteries and why we detect only a twofold increase in patients with coronary artery disease, even though greater than sixfold increases were detected in interstitial myocardial adenosine concentration in animal models of ischemia (27) . Finally, because of the small sample size-nine patients with coronary artery disease and six patients with normal epicardial coronary arteries-we must consider the results of this study to be only preliminary.
In summary, by using a double-lumen metabolic catheter, modified stop solution, and a simplified HPLC assay, we are able to detect an ischemia-induced twofold increase of coronary sinus adenosine in the absence of systemic dipyridamole. This is the first convincing demonstration that adenosine produced by ischemic myocardium in patients can escape from the interstitial space, cross the major metabolic endothelial barrier, and accumulate and be detected in coronary sinus blood.
